Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ruxolitinib

Abstract

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Ruxolitinib.

References

  1. 1

    Vannucchi, A. M. et al. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J. Clin. 59, 171–191 (2009).

    Article  Google Scholar 

  2. 2

    Quintás-Cardama, A. et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Rev. Drug Discov. 10, 127–140 (2011).

    Article  Google Scholar 

  3. 3

    Quintás-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010).

    Article  Google Scholar 

  4. 4

    US Food and Drug Administration. FDA labeling information — Jakafi. FDA website [online], (2011).

  5. 5

    Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363, 1117–1127 (2010).

    CAS  Article  Google Scholar 

  6. 6

    Silver, R. T. et al. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117, 6669–6672 (2011).

    CAS  Article  Google Scholar 

  7. 7

    Mesa, R. A. et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) Phase 2 trial E4903. Blood 116, 4436–4438 (2010).

    CAS  Article  Google Scholar 

  8. 8

    Cervantes, F. et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br. J. Haematol. 129, 771–775 (2005).

    CAS  Article  Google Scholar 

  9. 9

    Thepot, S. et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116, 3735–3742 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Ruben A. Mesa, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information Figure S1

First-line therapy of myelofibrosis in 2012. (PDF 702 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mesa, R., Yasothan, U. & Kirkpatrick, P. Ruxolitinib. Nat Rev Drug Discov 11, 103–104 (2012). https://doi.org/10.1038/nrd3652

Download citation

Further reading

Search

Quick links